Firms should have six weeks' worth of post-Brexit drug stockpiles by the end of 2020, the government says.Read more
A Carnival March will take place through central London by the 'Free the Vaccine Coalition', which wants any effective future Covid-19 vaccine to be available and affordable for all. They are asking scientific research bodies to sign up to an 'Open Covid Pledge' which will guarantee any successful vaccine research be free from copyright and patent. The group have released a lip-sync video to an updated version of Dolly Parton's 'Jolene' asking to free the vaccine. Donna Riddington, a spokesperson for the 'Free the Vaccine Coalition' explained the group's aims. (Photo: Free The Vaccine Coalition singing their cover of Jolene. Credit: Free The Vaccine Coalition)
The Indian pharma market grew just 2.4% in June compared to last year. That’s because fewer patients visited doctors and hospitals during the lockdown. But pharma companies are finding new opportunities. Piramal Pharma. one of India’s largest pharmaceutical companies, has adapted to changing demands during the pandemic. It is also betting on fresh funds from the US-based private equity firm Carlyle that has agreed to acquire a 20% stake in the company for about $490 million. Nandini Piramal, ED, Piramal Enterprises spearheaded the negotiations and talks to the BBC’s Devina Gupta about their next bets in the sector.
BBC Scotland Home Affairs correspondent
A Scottish life-sciences company is to manufacture a vaccine being trialled to combat the Covid-19 pandemic.
Stirling-based Symbiosis will manufacture the vaccine for the pharmaceutical giant AstraZeneca as it undergoes clinical trials.
The vaccine, known as AZD 1222, is currently in clinical trials across the UK.
Under the new agreement, Symbiosis, which employs 100 staff in its Stirling headquarters, will provide manufacturing capacity for the clinical trial which it hopes will accelerate the further development of the vaccine.
AstraZeneca has said it will provide the drug at cost during the pandemic. The first doses should be available by the end of the year.
Using manufacturing capacity across the world, including in Scotland, means the company should be able to supply two billion doses if regulatory approval is granted.